Successful Regional Delivery and Long-term Expression of a Dystrophin Gene in Canine Muscular Dystrophy: A Preclinical Model for Human Therapies
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Duchenne muscular dystrophy (DMD) is a fatal, X-linked muscle disease caused by mutations in the dystrophin gene. Adeno-associated viral (AAV) vector-mediated gene replacement strategies hold promise as a treatment. Studies in animal models and human trials suggested that immune responses to AAV capsid proteins and transgene products prevented efficient gene therapy. In this study, we used widespread intramuscular (i.m.) injection to deliver AAV6-canine micro-dystrophin (c-µdys) throughout a group of skeletal muscles in dystrophic dogs given a brief course of commonly used immunosuppressants. Robust c-µdys expression was obtained for at least two years and was associated with molecular reconstitution of the dystrophin-glycoprotein complex (DGC) at the muscle membrane. Importantly, c-µdys expression was maintained for at least 18 months after discontinuing immunosuppression. The results obtained in a relevant preclinical model of DMD demonstrate feasibility of widespread AAV-mediated muscle transduction and transgene expression in the presence of transient immunosuppression to achieve molecular reconstitution that can be directly translated to human trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Dystrophin Immunity in Duchenne's Muscular Dystrophy
Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000228 · Cited by 655
Systemic delivery of genes to striated muscles using adeno-associated viral vectors
Gregorevic, P., Blankinship, M. J., Allen, J. M., Crawford, R. W., Meuse, L., Miller, D. G., Russell, D. W., & Chamberlain, J. S. (2004) · Nature Medicine · doi:10.1038/nm1085 · Cited by 620
Self-citationPhase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector
Bowles, D. E., McPhee, S. W., Li, C., Gray, S. J., Samulski, J. J., Camp, A. S., Li, J., Wang, B., Monahan, P. E., Rabinowitz, J. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.237 · Cited by 400
Mingozzi, F., Meulenberg, J. J., Hui, D. J., Basner-Tschakarjan, E., Hasbrouck, N. C., Edmonson, S. A., Hutnick, N. A., Betts, M. R., Kastelein, J. J., Stroes, E. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-167510 · Cited by 295
Mendell, J. R., Rodino‐Klapac, L. R., Rosales, X. Q., Coley, B. D., Galloway, G., Lewis, S., Malik, V., Shilling, C., Byrne, B. J., Conlon, T., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22251 · Cited by 248
Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models
Rapti, K., Louis-Jeune, V., Kohlbrenner, E., Ishikawa, K., Ladage, D., Zolotukhin, S., Hajjar, R. J., & Weber, T. (2012) · Molecular Therapy · doi:10.1038/mt.2011.177 · Cited by 170
Long‐term functional adeno‐associated virus‐microdystrophin expression in the dystrophic CXMDj dog
Koo, T., Okada, T., Athanasopoulos, T., Foster, H., Takeda, S., & Dickson, G. (2011) · The Journal of Gene Medicine · doi:10.1002/jgm.1602 · Cited by 74
Gregorevic, P., Schultz, B. R., Allen, J. M., Halldorson, J. B., Blankinship, M. J., Meznarich, N. A., Kuhr, C. S., Doremus, C., Finn, E., Liggitt, D., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.116 · Cited by 40
Self-citation
Research works printed but not linked: 38
- Muntoni, 2003, Dystrophin and mutations: one gene, several proteins, multiple phenotypes, Lancet Neurol, 2, 731, 10.1016/S1474-4422(03)00585-4 · DOI · Paper page
- Ahn, 1993, The structural and functional diversity of dystrophin, Nat Genet, 3, 283, 10.1038/ng0493-283 · DOI · Paper page
- Wang, 2009, Gene therapy in large animal models of muscular dystrophy, ILAR J, 50, 187, 10.1093/ilar.50.2.187 · DOI
- Mendell, 2009, Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins, Ann Neurol, 66, 290, 10.1002/ana.21732 · DOI · Paper page
- Wang, 2011, Immunity and AAV-Mediated Gene Therapy for Muscular Dystrophies in Large Animal Models and Human Trials, Front Microbiol, 2, 201, 10.3389/fmicb.2011.00201 · DOI · Paper page
- Hoffman, 2011, Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through, Am J Pathol, 179, 12, 10.1016/j.ajpath.2011.03.050 · DOI
- Aartsma-Rus, 2010, New insights in gene-derived therapy: the example of Duchenne muscular dystrophy, Ann N Y Acad Sci, 1214, 199, 10.1111/j.1749-6632.2010.05836.x · DOI
- Vilquin, 2011, Cell therapy for muscular dystrophies: advances and challenges, Curr Opin Organ Transplant, 16, 640, 10.1097/MOT.0b013e32834cfb70 · DOI
- Negroni, 2011, Current advances in cell therapy strategies for muscular dystrophies, Expert Opin Biol Ther, 11, 157, 10.1517/14712598.2011.542748 · DOI
- Palmieri, 2010, Past, present and future of myoblast transplantation in the treatment of Duchenne muscular dystrophy, Pediatr Transplant, 14, 813, 10.1111/j.1399-3046.2010.01377.x · DOI
- Wang, 2007, Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy, Hum Gene Ther, 18, 18, 10.1089/hum.2006.093 · DOI · Paper page
- Yue, 2008, A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs, Mol Ther, 16, 1944, 10.1038/mt.2008.207 · DOI · Paper page
- Yuasa, 2007, Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products, Gene Ther, 14, 1249, 10.1038/sj.gt.3302984 · DOI
- Ohshima, 2009, Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle, Mol Ther, 17, 73, 10.1038/mt.2008.225 · DOI · Paper page
- Wang, 2010, Immune responses to AAV in canine muscle monitored by cellular assays and noninvasive imaging, Mol Ther, 18, 617, 10.1038/mt.2009.294 · DOI
- Wang, 2007, Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression, Mol Ther, 15, 1160, 10.1038/sj.mt.6300161 · DOI · Paper page
- Lapidos, 2004, The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma, Circ Res, 94, 1023, 10.1161/01.RES.0000126574.61061.25 · DOI · Paper page
- Ervasti, 1991, Membrane organization of the dystrophin-glycoprotein complex, Cell, 66, 1121, 10.1016/0092-8674(91)90035-W · DOI · Paper page
- Tidball, 1991, Force transmission across muscle cell membranes, J Biomech, 24, 43, 10.1016/0021-9290(91)90376-X · DOI · Paper page
- Tidball, 1991, Dystrophin is required for normal thin filament-membrane associations at myotendinous junctions, Am J Pathol, 138, 17
- Banks, 2010, The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins, PLoS Genet, 6, e1000958, 10.1371/journal.pgen.1000958 · DOI · Paper page
- Herson, 2011, A phase I dose-escalating study of AAV1–γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C, Mol Ther, 19, S20
- Kornegay, 2010, Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs, Mol Ther, 18, 1501, 10.1038/mt.2010.94 · DOI · Paper page
- Halbert, 2010, Expression of human alpha1-antitrypsin in mice and dogs following AAV6 vector-mediated gene transfer to the lungs, Mol Ther, 18, 1165, 10.1038/mt.2010.51 · DOI
- Shin, 2012, Humoral immunity to AAV-6, 8, and 9 in normal and dystrophic dogs, Hum Gene Ther, 23, 287, 10.1089/hum.2011.125 · DOI · Paper page
- Arnett, 2011, Immune Responses to rAAV6: The Influence of Canine Parvovirus Vaccination and Neonatal Administration of Viral Vector, Front Microbiol, 2, 220, 10.3389/fmicb.2011.00220 · DOI
- Storb, 1997, Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation, Blood, 89, 3048, 10.1182/blood.V89.8.3048 · doi:10.1182/blood.v89.8.3048
- Yu, 1998, Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts, Blood, 91, 2581, 10.1182/blood.V91.7.2581 · doi:10.1182/blood.v91.7.2581
- Storb, 1973, Treatment of established graft-versus-host disease in dogs by antithymocyte serum or prednisone, Blood, 42, 601, 10.1182/blood.V42.4.601.601 · doi:10.1182/blood.v42.4.601.601
- Storb, 1974, Effect of prior blood transfusions on marrow grafts: abrogation of sensitization by procarbazine and antithymocyte serum, J Immunol, 112, 1508, 10.4049/jimmunol.112.4.1508 · doi:10.4049/jimmunol.112.4.1508
- Storb, 1974, Treatment of established human graft-versus-host disease by antithymocyte globulin, Blood, 44, 56, 10.1182/blood.V44.1.57.57 · doi:10.1182/blood.v44.1.57.57
- Storb, 1994, Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia, Blood, 84, 941, 10.1182/blood.V84.3.941.941 · doi:10.1182/blood.v84.3.941.941
- Kahl, 2005, Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up, Br J Haematol, 130, 747, 10.1111/j.1365-2141.2005.05667.x · DOI
- Dell'Agnola, 2004, Hematopoietic stem cell transplantation does not restore dystrophin expression in Duchenne muscular dystrophy dogs, Blood, 104, 4311, 10.1182/blood-2004-06-2247 · DOI
- Blankinship, 2004, Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6, Mol Ther, 10, 671, 10.1016/j.ymthe.2004.07.016 · DOI · Paper page
- Rafael, 1996, Forced expression of dystrophin deletion constructs reveals structure-function correlations, J Cell Biol, 134, 93, 10.1083/jcb.134.1.93 · DOI · Paper page
- Banks, 2008, Molecular and cellular adaptations to chronic myotendinous strain injury in mdx mice expressing a truncated dystrophin, Hum Mol Genet, 17, 3975, 10.1093/hmg/ddn301 · DOI
- Halbert, 2006, Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors, Hum Gene Ther, 17, 440, 10.1089/hum.2006.17.440 · DOI · Paper page
Cited by
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“140 Despite the potential risk of transgene immune responses, muscle is an important target tissue not only for diseases like muscular dystrophies, but also for protein de fi ciencies in which liver (the main site of synthesis of several of these proteins) is compromised and cannot be used as the…”
Duchenne and Becker Muscular Dystrophies
Flanigan, K. M. (2014) · Neurologic Clinics · doi:10.1016/j.ncl.2014.05.002 · Cited by 317
Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy
Le Guiner, C., Servais, L., Montus, M., Larcher, T., Fraysse, B., Moullec, S., Allais, M., François, V., Dutilleul, M., Malerba, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms16105 · Cited by 246
Twenty-Five Years of Structural Parvovirology
Mietzsch, M., Pénzes, J. J., & Agbandje-McKenna, M. (2019) · Viruses · doi:10.3390/v11040362 · Cited by 197
Childers, M. K., Joubert, R., Poulard, K., Moal, C., Grange, R. W., Doering, J. A., Lawlor, M. W., Rider, B. E., Jamet, T., Danièle, N., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007523 · Cited by 173
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“and MMF prevented the immune responses and achieved transgene expression in a canine study [231].”
BackgroundManufacturing of recombinant adeno-associated viruses using mammalian expression platforms
Robert, M., Chahal, P. S., Audy, A., Kamen, A., Gilbert, R., & Gaillet, B. (2017) · Biotechnology Journal · doi:10.1002/biot.201600193 · Cited by 89
Inhibition of antigen presentation during AAV gene therapy using virus peptides
Shao, W., Chen, X., Samulski, R. J., Hirsch, M. L., & Li, C. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddx427 · Cited by 17
Metadata
- Authors
- Wang, Z., Storb, R., Halbert, C. L., Banks, G. B., Butts, T. M., Finn, E. E., Allen, J. M., Miller, A. D., Chamberlain, J. S., & Tapscott, S. J.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2012-08
- Volume
- 20
- Issue
- 8
- Pages
- 1501-1507
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2032902046
- Cited by
- 78
- References
- 10
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 1528 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.